Key facts
- CNSP - CNS Pharmaceuticals, Inc. has 14 insiders with reported activity on this page.
- Net insider value flow over the last year: +$34,002.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 14 Insiders of CNS Pharmaceuticals, Inc.
- Symbol
- CNSP on Nasdaq
- Location
- Houston, TX
Change
- Buy value: $34,002; sell value: $0.
- Net share flow: +7,100.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$34,002.
Buys
$34,002
Shares: 7,100
Insiders: 1
Sells
$0
Shares: 0
Insiders: 0
Net
+$34,002
Shares: +7,100
Insiders: 1
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 7,100 | 0 | $34,002 | $0 | +$34,002 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
CNS Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Waldemar Priebe | 10%+ Owner | $198,486 | Mixed | 06 Dec 2022 | ||
| Cortice Biosciences, Inc. | 10%+ Owner | $172,010 | Mixed | 30 Jul 2024 | ||
| Carl Anthony Evans | Director | $54,165 | Mixed | 08 Apr 2024 | ||
| Faith L. Charles | Director | $34,001 | +$34,002 | +100% | Filing P/S | 18 May 2026 |
| Jerzy Gumulka | Director | Mixed | 17 Nov 2025 | |||
| Andrzej Andraczke | Director | Mixed | 21 Sep 2023 | |||
| Christopher Downs | Chief Financial Officer | Mixed | 17 Nov 2025 | |||
| Rami Levin | CEO and President, Director | Mixed | 01 Jan 2026 | |||
| Steve O'Loughlin | Chief Financial Officer | Mixed | 02 Mar 2026 | |||
| Amy Mahery | Director | Mixed | 17 Nov 2025 | |||
| Eric Faulkner | Chief Technology Officer | Mixed | 02 Mar 2026 | |||
| Bettina M. Cockroft | Director | Mixed | 17 Nov 2025 | |||
| John M. Climaco | Chief Executive Officer, Director | Mixed | 17 Nov 2025 | |||
| Jeffry R. Keyes | Director | Mixed | 17 Nov 2025 |
Top shareholders of CNS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Stonepine Capital Management, LLC |
13D/G
13F
|
Company |
9.9%
|
159,790
|
$402,671 | +$279,627 | 31 Mar 2026 | |
| Ikarian Capital, LLC |
13D/G
13F
|
Company |
5.7%
|
45,830
|
$118,700 | $0 | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13D/G
|
— |
5%
|
30,177
|
$5,432 | -$95,575 | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
23,189
|
$55,653 | — | 31 Mar 2026 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.84%
|
13,524
|
$32,322 | — | 31 Mar 2026 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.08%
|
1,310
|
$3,131 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.05%
|
729
|
$1,742 | — | 31 Mar 2026 | |
| BARRETT & COMPANY, INC. |
13F
|
Company |
0%
|
8
|
$19 | — | 31 Mar 2026 | |
| MAI Capital Management |
13F
|
Company |
0%
|
3
|
$8 | — | 31 Mar 2026 | |
| Caitong International Asset Management Co., Ltd |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Mar 2026 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Mar 2026 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$2 | — | 31 Mar 2026 | |
| Waldemar Priebe |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
156,807
|
$198,486 | — | 06 Dec 2022 | |
| Cortice Biosciences, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
573,368
|
$172,010 | — | 30 Jul 2024 | |
| Carl Anthony Evans |
3/4/5
|
Director |
—
mixed-class rows
|
501,001
mixed-class rows
|
$54,165 | — | 08 Apr 2024 | |
| Faith L. Charles |
3/4/5
|
Director |
—
mixed-class rows
|
8,617
mixed-class rows
|
$34,001 | +$34,002 | 18 May 2026 | |
| Sound Income Strategies, LLC |
13F
|
Company |
—
class O/S missing
|
16
|
$36 | — | 31 Mar 2026 | |
| Andrzej Andraczke |
3/4/5
|
Director |
—
class O/S missing
|
45,428
|
— | — | 21 Sep 2023 | |
| Rami Levin |
3/4/5
|
CEO and President, Director |
—
class O/S missing
|
19,000
|
— | — | 01 Jan 2026 | |
| John M. Climaco |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
9,761
|
— | — | 17 Nov 2025 | |
| Eric Faulkner |
3/4/5
|
Chief Technology Officer |
—
class O/S missing
|
9,500
|
— | — | 02 Mar 2026 | |
| Steve O'Loughlin |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
9,500
|
— | — | 02 Mar 2026 | |
| Christopher Downs |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
4,881
|
— | — | 17 Nov 2025 | |
| Amy Mahery |
3/4/5
|
Director |
—
class O/S missing
|
1,517
|
— | — | 17 Nov 2025 | |
| Bettina M. Cockroft |
3/4/5
|
Director |
—
class O/S missing
|
1,517
|
— | — | 17 Nov 2025 | |
| Jeffry R. Keyes |
3/4/5
|
Director |
—
class O/S missing
|
1,517
|
— | — | 17 Nov 2025 | |
| Jerzy Gumulka |
3/4/5
|
Director |
—
class O/S missing
|
1,517
|
— | — | 17 Nov 2025 |
Recent Insider Transactions by Companies or Individuals for CNS Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Faith L. Charles | CNSP | Common Stock | Purchase | $34,002 | $4.79 | 7,100 | 7,100 | 18 May 2026 | Direct | |
| Eric Faulkner | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Steve O'Loughlin | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Rami Levin | CNSP | Restricted Stock Units | Award | 19,000 | 19,000 | 01 Jan 2026 | Direct | |||
| Jeffry R. Keyes | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Bettina M. Cockroft | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| John M. Climaco | CNSP | Option to purchase common stock | Award | 9,761 | 9,761 | 17 Nov 2025 | Direct | |||
| Amy Mahery | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Faith L. Charles | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Christopher Downs | CNSP | Option to purchase common stock | Award | 4,881 | 4,881 | 17 Nov 2025 | Direct | |||
| Jerzy Gumulka | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.